drugset
drugset / Trial / NCT03929107

Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.

NCT03929107 ↗

Phase 2 Unknown 80 enrolled Wenbin Qian Zhejiang Provincial Tongde Hospital · collab
NaSingle-groupOpen-labelTreatment

Summary

It's a single arm, open label prospective study, in which the safety and efficacy of Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T therapy are evaluated in refractory/relapsed B cell lymphoma patients.

Timeline

Start
2019-03-28
Primary completion
2022-01-31
Completion
2022-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Interleukin-7 Protein / enzyme biologic — —

Indications

lymphoma